Bafna Pharmaceuticals (NSE:BAFNAPH) EBIT: ₹146 Mil (TTM As of Mar. 2026)


NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
59 GF Score
Price ₹194.68
GF Value ₹90.54
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals EBIT?

Bafna Pharmaceuticals NSE:BAFNAPH +5.00% 59 EBIT is ₹146 Mil as of Mar. 2026. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 59/100 and a GF Value™ of ₹90.54 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Bafna Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹36 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹146 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bafna Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was 5.37%. Bafna Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.95%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bafna Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.91%.

Bafna Pharmaceuticals  (NSE:BAFNAPH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bafna Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=75.476 * ( 1 - 0% )/( (0 + 1405.095)/ 1 )
=75.476/1405.095
=5.37 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1755.324 - 312.859 - ( 37.37 - max(0, 571.896 - 896.521+37.37))
=1405.095

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Bafna Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=145.94/( ( (0 + max(0, 0)) + (849.242 + max(482.992, 0)) )/ 1 )
=145.94/( ( 0 + 1332.234 )/ 1 )
=145.94/1332.234
=10.95 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(439.292 + 289.03 + 130.055) - (312.859 + 0 + 62.526)
=482.992

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bafna Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=146.313/5032.745
=2.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals EBIT Related Terms

Bafna Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals EBIT Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.41 134.14 92.85 68.84 146.31

Bafna Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.33 42.94 39.89 26.99 36.49

NSE:BAFNAPH vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bafna Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bafna Pharmaceuticals's EV-to-EBIT falls into.


NSE:BAFNAPH
59GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹146 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹146 Mil mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a EBIT of ₹146 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bafna Pharmaceuticals.
Is Bafna Pharmaceuticals' EBIT too high?
Bafna Pharmaceuticals' current EBIT is ₹146 Mil. Overall, Bafna Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' EBIT compare to ZTS?
Bafna Pharmaceuticals' EBIT of ₹146 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bafna Pharmaceuticals. Bafna Pharmaceuticals's current EBIT is ₹146 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.54, compared to a current price of ₹194.68 — trading 115% above its estimated fair value. The current EBIT is ₹146 Mil. Bafna Pharmaceuticals' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current EBIT is ₹146 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹194.68 is trading 115% above its estimated GF Value™ of ₹90.54. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • EBIT: ₹146 Mil
  • GF Value™: ₹90.54 vs. price of ₹194.68 (115% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
59GF Score

Get the complete analysis for NSE:BAFNAPH

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹194.68
Price
₹90.54
GF Value